Ligand Pharmaceuticals Inc. (LGND) Stock Research, Analysis & News

Quick Analysis on Ligand Pharmaceuticals Inc. (LGND) Stock as of November 22, 2019

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Ligand Pharmaceuticals Inc. (LGND) Stock below)

Ligand Pharmaceuticals Inc. (LGND) Stock Profile Summary

Ligand Pharmaceuticals Incorporated, a biotechnology company, focuses on the discovery and development of pharmaceuticals for the critical unmet medical needs in the United States. It offers Avinza for the treatment of chronic pain; and Eltrombopag/Promacta for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP). The companys products under food and drug administration review comprise Bazedoxifene and Lasofoxifene to treat osteoporosis; and Eltrombopag/Revolade for the treatment of ITP. Its products under Phase III include Bazedoxifene/Premarin for menopausal symptoms; and Eltrombopag to treat hepatitis C and chronic liver disease. The companys products under Phase II consist of PS433540, a dual acting receptor agonist that targets the angiotensin and endothelin receptors; LGD-4665 for the treatment of ITP; Eltrombopag to treat oncology related thrombocytopenia; PS291822 to prevent COPD and asthma; and PS540446 for the treatment of psoriasis and atherosclerosis. Ligands products under Phase I comprise Eltrombopag to treat oncology related thrombocytopenia; PS095760 for leukemia; PS386113 and PS873266 for inflammation; PS948115 to treat respiratory diseases; PS248288 for the treatment of metabolic related diseases; and PS178990 for muscle wasting. Its products under preclinical stage consist of BACE inhibitor for the treatment of Alzheimers disease; LGD-4033 for muscle wasting; CCR1 antagonist and glucocorticoid receptor modulator for inflammation; Erythropoietin receptor agonist for hematological indications; and receptor modulators for androgen independent prostate cancer. Ligand has research and development collaborations with pharmaceutical companies, including GlaxoSmithKline; Wyeth; Pfizer, Inc.; Schering-Plough Ltd.; Bristol-Myers Squibb Company; Cephalon, Inc.; Celgene Corporation; and Trevena. The company was founded in 1987 and is based in San Diego, California.

Ligand Pharmaceuticals Inc. (LGND) Stock Key Statistics Research and Analysis as of November 22, 2019

Ligand Pharmaceuticals Inc. (LGND) Stock Competitor Research and Analysis

Eli Lilly & Co. (LLY)Merck & Co. Inc. (MRK)
Amgen Inc. (AMGN)Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)
Bristol-Myers Squibb Company (BMY)

Mutual Funds with Ligand Pharmaceuticals Inc. (LGND) Stock in its top 10 holdings

FundCategoryLGND Holding Percentage
AllianzGI US Small-Cap Growth InstlSmall Growth1.47%
Conestoga Small Cap InvestorsSmall Growth2.86%

ETFs with Ligand Pharmaceuticals Inc. (LGND) Stock in its top 10 holdings

Stock Research on Ligand Pharmaceuticals Inc. (LGND)

Latest Market News on Ligand Pharmaceuticals Inc. (LGND)


Click here to find the latest news on Ligand Pharmaceuticals Inc. (LGND)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Eli Lilly & Co. (LLY)
Merck & Co. Inc. (MRK)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)
Bristol-Myers Squibb Company (BMY)